Table 2 Urinary diary parameters and OAB questionnaire scores in both groups at pre-treatment, 1-month, and 6-month post-treatment (Mean ± SD)(Mean ± SD).

From: Ultrasound guided transabdominal botulinum toxin injection for refractory overactive bladder treatment

Observational indicators

Observation group (n = 32)

Control group(n = 32)

P value

Daytime voiding frequency (times/day)

Pre-treatment

16.82 ± 7.61

15.34 ± 8.47

0.465

1-mo Post-treatment

8.46 ± 2.15*

9.25 ± 2.64*

0.194

6-mo Post-treatment

11.53 ± 3.26*#

12.05 ± 1.86*#

0.436

Nocturia episodes (times/night)

Pre-treatment

6.69±1.38

7.24 ± 1.85

0.183

1-mo Post-treatment

2.35 ± 0.96*

2.57 ± 1.21*

0.424

6-mo Post-treatment

5.76 ± 2.56#

6.25 ± 2.37#

0.430

Urgency episodes (times/day)

Pre-treatment

6.98 ± 1.67

7.25 ± 1.94

0.553

1-mo Post-treatment

2.31 ± 0.85*

2.54 ± 1.02*

0.331

6-mo Post-treatment

3.65 ± 0.81*#

3.81 ± 1.21*#

0.537

Initial bladder capacity(mL)

Pre-treatment

90.52 ± 25.69

95 ± 42.72

0.613

1-mo Post-treatment

162.67 ± 33.25*

157 ± 45.38*

0.571

6-mo Post-treatment

130.51 ± 27.84*#

136 ± 35.16*#

0.491

Maximum bladder capacity(mL)

Pre-treatment

278.71 ± 67.82

297.63 ± 82.74

0.321

1-mo Post-treatment

412.69 ± 105.28*

455.28 ± 95.78*

0.096

6-mo Post-treatment

378.58 ± 95.73*#

387.52 ± 104.75*#

0.723

ICIQ-OAB score(0–16)

Pre-treatment

12.93 ± 2.82

14.02 ± 2.12

0.086

1-mo Post-treatment

8.91 ± 1.38*

9.17 ± 2.37*

0.594

6-mo Post-treatment

9.62 ± 1.57*

10.85 ± 3.59*#

0.081

OAB-Q score(1–6)

Pre-treatment

4.35 ± 1.12

4.67 ± 1.58

0.354

1-mo Post-treatment

2.27 ± 0.76*

2.52 ± 0.94*

0.247

6-mo Post-treatment

3.01 ± 0.64*#

2.89 ± 1.52*

0.682

  1. Note: Abbreviations: ICIQ-OAB, Overactive Bladder module of the International Consultation on Incontinence Questionnaire; OAB-Q, Overactive Bladder Questionnaire. *P < 0.05 vs. Pre-treatment; #P < 0.05 vs. 1-mo Post-treatment.
Back to article page